Background: Thromboembolism is a relatively common complication of chronic heart failure (HF) and the place of antiplatelet therapy is uncertain. Objectives: We characterized the rate of thromboxane and prostacyclin biosynthesis in chronic HF of ischemic origin, with the aim of separating the influence of HF on platelet activation from that of the underlying ischemic heart disease (IHD). Patients and Methods: We compared urinary 11-dehydro-thromboxane (TX)B(2), 2,3 dinor 6-keto-PGF(1 alpha,) 8-iso-prostaglandin (PG)F(2 alpha), and plasma N-terminal pro-brain natriuretic peptide (NT-pro-BNP), asymmetric dimethylarginine (ADMA), and soluble CD40 ligand (sCD40L), in 84 patients with HF secondary to IHD, 61 patients with IHD without HF and 42 h...
BACKGROUND: To be fully activated platelets are dependent on two positive feedback loops; the format...
BACKGROUND: Systemic thromboxane generation, not suppressible by standard aspirin therapy and likely...
High levels of thromboxane A2 (TxA2), a key mediator of platelet activation and aggregation, are ass...
Background: Thromboembolism is a relatively common complication of chronic heart failure (HF) and th...
Overview analysis of indirect comparisons in clinical trials - showing saturation of the antithrombo...
BACKGROUND: Thrombotic events still occur in aspirin-treated patients with coronary artery disease. ...
BACKGROUND AND PURPOSE: Enhanced thromboxane (TX) biosynthesis has previously been reporte...
BackgroundDespite dual antiplatelet treatment with the new P2Y12 platelet receptor antagonists (P2Y1...
AbstractObjectives. We sought to study the dose dependence of in vivo suppression by aspirin of enha...
ObjectivesWe investigated whether use of low-dose enteric-coated (EC) aspirin for secondary preventi...
We studied the influence of cardiovascular(CV) risk factors, previous CV events, and co-treatments w...
Introduction: Aspirin (ASA) irreversibly inhibits platelet cyclooxygenase-1 (COX-1) leading to decre...
BACKGROUND: Poor clinical outcome in aspirin-treated patients has been termed aspirin resistance and...
BACKGROUND: The antithrombotic efficacy of aspirin is attributed to its inhibition of the enzyme pro...
Introduction: There is emerging evidence of a considerable variability of the impact of aspirin on c...
BACKGROUND: To be fully activated platelets are dependent on two positive feedback loops; the format...
BACKGROUND: Systemic thromboxane generation, not suppressible by standard aspirin therapy and likely...
High levels of thromboxane A2 (TxA2), a key mediator of platelet activation and aggregation, are ass...
Background: Thromboembolism is a relatively common complication of chronic heart failure (HF) and th...
Overview analysis of indirect comparisons in clinical trials - showing saturation of the antithrombo...
BACKGROUND: Thrombotic events still occur in aspirin-treated patients with coronary artery disease. ...
BACKGROUND AND PURPOSE: Enhanced thromboxane (TX) biosynthesis has previously been reporte...
BackgroundDespite dual antiplatelet treatment with the new P2Y12 platelet receptor antagonists (P2Y1...
AbstractObjectives. We sought to study the dose dependence of in vivo suppression by aspirin of enha...
ObjectivesWe investigated whether use of low-dose enteric-coated (EC) aspirin for secondary preventi...
We studied the influence of cardiovascular(CV) risk factors, previous CV events, and co-treatments w...
Introduction: Aspirin (ASA) irreversibly inhibits platelet cyclooxygenase-1 (COX-1) leading to decre...
BACKGROUND: Poor clinical outcome in aspirin-treated patients has been termed aspirin resistance and...
BACKGROUND: The antithrombotic efficacy of aspirin is attributed to its inhibition of the enzyme pro...
Introduction: There is emerging evidence of a considerable variability of the impact of aspirin on c...
BACKGROUND: To be fully activated platelets are dependent on two positive feedback loops; the format...
BACKGROUND: Systemic thromboxane generation, not suppressible by standard aspirin therapy and likely...
High levels of thromboxane A2 (TxA2), a key mediator of platelet activation and aggregation, are ass...